TruScreen Recognised in Authoritative China Blue Paper

NZX/ASX Announcement
8 May 2023
TruScreen Recognised in Authoritative China Blue Paper – “Cervical Cancer Three Stage
Standardised Prevent and Treat”

Highlights
• Authoritative China Blue Paper recognises TruScreen in section “Artificial Intelligence
for Cervical Cancer Screening”
• The publication highlights the benefits of TruScreen as a primary cervical cancer
screening method
• Blue Paper concludes TruScreen has important role to play emphasising real time
results, ease of training and operation and conclusive positive body of clinical evidence
• The Blue Paper references TruScreen having a better sensitivity and specificity than
Liquid Based Cytology (LBC) and better specificity than an HPV test
• Acknowledgement expected to assist TruScreen distributors in accelerating sales

Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that it has been recognised in a China
Blue Paper “Cervical Cancer Three Stage Standardized Prevent and Treatment” published on 28 April
2023. In China Blue Papers are promulgated to act as the definitive position on leading edge
developments in all industries in China and are recognised as an endorsement by the leaders in the
relevant field.

The publication presents a consensus on the most successful and innovative technologies and
methods to eradicate cervical cancer in China, in line with the World Health Organisation (WHO)
strategy. The paper was the result of four years of research and collaboration by many experts in
gynaecology, including a number of leaders
1
in the field who attended the publication launch.

The Blue Paper specifically highlights TruScreen in a section titled “Artificial Intelligence Technology
For Cervical Cancer Screening”, describing it’s origin, substantial clinical trials, and the benefits of
using TruScreen as a standalone primary cervical cancer screening method, which has demonstrated
superior sensitivity and specificity results, in comparison to screening of LBC and HPV.

The publication also recognises the TruScreen device’s objective and real time results, ease of
training and operation and conclusive positive body of clinical evidence from multi-centre clinical
studies.

CEO, Dr Beata Edling commented, “we are delighted that TruScreen has been endorsed in this
prestigious publication published by eminent oncology and gynaecology institutions.
2
TruScreen will
continue to work with Beijing Siweixiangtai Tech Co Ltd (SWXT), our distributor in China to further
accelerate their sales growth.”
This announcement has been approved by the Board.

1
the past Chairman of The Chinese Obstetricians and Gynaecologists Association (COGA ) Professor Lang Jinhe, the newly
appointed COGA Chairman Professor Di Wen, Chinese Society for Colposcopy and Cervical Pathology (CSCCP)
Chairwomen Professor Wei Lihui, the head of Women and Children's Health Division of National Health Commission Xu
Xiaochao, Secretary General of China Preventive Healthcare Association Zhang Lingli.
2
Chinese Association of Gynaecologists Oncologists (COGA), Cervical Cancer Prevention and Control Research
Committee of China, Women and Children's Health Research Institute, Cancer Prevention and Control Professional
Committee of China Preventive Healthcare Association, National Healthcare Industry Entity Management
Association, and the Genital Health Division of China Population Culture Promotion Association.

For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com
Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra®, is registered as a primary screening tool for cervical cancer
screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the
TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and
COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Zimbabwe, Israel, Ukraine,
and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen
established a manufacturing facility in China for devices marketed and sold in China.
To date, over 170000* examinations have been performed with TruScreen device and over 200
devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi
Arabia. TruScreen’s vision is “A world without the cervical cancer
©
”.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with
a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve
the cells. Then it is sent to a laboratory for a pathologist to examine under a
microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-
procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the
cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other
tests can be done at the same time, such as the human papillomavirus (HPV)
test https://www.cancer.net/cancer-types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same
sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly
linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC.
This test may also be done on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which reports the
presence or absence of a condition. If individuals who have the condition are considered "positive"
and those who don't are considered "negative", then sensitivity is a measure of how well a test can
identify true positives and specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on the
individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on
the individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and
Australia, please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)
Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council